INFLAMMATORY BOWEL DISEASE MARKET ANALYSIS

Inflammatory Bowel Disease Market, By Drug Class (Corticosteroids, Aminosalicylates, TNF Inhibitors, Immunosuppressant, Antibiotics, Others), By Disease Indication (Ulcerative Colitis and Crohn’s Disease), By Route of Administration (Oral and Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

In May 2024, Johnson & Johnson Services announced positive phase 3 results for Tremfya in its Crohn’s disease program, demonstrating superiority over Stelara in all endoscopic patients in the trial.
In April 2024, Takeda Pharmaceutical Company Limited received FDA approval for the subcutaneous administration of Entyvio following induction therapy with intravenous Entyvio, for treating patients with severely active Crohn’s Disease.
In October 2023, Johnson & Johnson Services Inc. reported phase 3 trial data for Tremfya in active ulcerative colitis, showing a 77% overall clinical response rate and early symptom improvement.
In June 2023, Lilly's Omvoh (mirikizumab) received market authorization from the UK's MHRA for treating ulcerative colitis.
In February 2023, AbbVie announced that the UK's MHRA approved RINVOQ, a JAK inhibitor, for moderate to severe Crohn's disease in patients who did not respond adequately to conventional therapy.
In January 2023, Inotrem, a clinical-stage biotechnology company, received funding from the Crohn's & Colitis Foundation to support the development of innovative therapeutic approaches for Crohn's disease and ulcerative colitis.